Cite

    Pontes, F. et al. (n.d.). 293OSurvival outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting. Annals of oncology. p. . [Online].